Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18673671 | IONIZABLE CATIONIC LIPIDS | May 2024 | December 2025 | Allow | 19 | 1 | 0 | No | No |
| 18504859 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | November 2023 | July 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18555233 | NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18212444 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | June 2023 | July 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18033317 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | April 2023 | December 2025 | Allow | 32 | 1 | 0 | No | No |
| 18041540 | PYRIMIDINE RING COMPOUND | February 2023 | November 2025 | Allow | 33 | 0 | 1 | No | No |
| 18106273 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18040552 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18010731 | TREATMENT FOR HUMAN CORONAVIRUS INFECTION | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18007940 | ROR gamma t Inhibitors and Topical Uses Thereof | December 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17925854 | HETEROCYCLIC COMPOUNDS AS STING MODULATORS | November 2022 | November 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17925493 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17997675 | PREPARATION OF COMPOUNDS HAVING PESTICIDAL ACTIVITY | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17918791 | PIRFENIDONE FOR CORONAVIRUS TREATMENT | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | Yes | No |
| 17915376 | STAINING METHOD, MICROSCOPIC OBSERVATION METHOD, STAINING AGENT AND STAINING KIT | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17954152 | CYTOTOXIC AGENTS | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17934772 | COMPOUNDS, COMPOSITIONS AND METHODS | September 2022 | July 2025 | Allow | 34 | 1 | 0 | No | No |
| 17905076 | COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF PANCREATIC DISEASES AND CONDITIONS | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17875770 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | July 2022 | March 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17740624 | Compositions and Methods for Treating Cancer | May 2022 | January 2026 | Abandon | 45 | 2 | 0 | No | No |
| 17734413 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | May 2022 | May 2025 | Abandon | 36 | 2 | 0 | Yes | No |
| 17755366 | CD4 MIMIC COMPOUND WITH ANTI-HIV ACTIVITY | April 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17699061 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | March 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17695162 | PROTECTION OF PLANT EXTRACTS AND COMPOUNDS FROM DEGRADATION | March 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17632004 | a-Substituted Phenyl Structure-Containing Compound, Preparation Method Thereof, and Disinfectant | February 2022 | April 2025 | Abandon | 38 | 3 | 1 | Yes | No |
| 17626029 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | January 2022 | September 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17602206 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | October 2021 | February 2025 | Abandon | 40 | 1 | 0 | Yes | No |
| 17221178 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | April 2021 | February 2025 | Abandon | 47 | 2 | 1 | No | No |
| 15422264 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | February 2017 | June 2018 | Abandon | 16 | 1 | 0 | No | No |
| 15411510 | BENZISOXAZOLES | January 2017 | January 2018 | Abandon | 11 | 1 | 0 | No | No |
| 15400820 | C5AR ANTAGONISTS | January 2017 | November 2017 | Abandon | 10 | 1 | 0 | No | No |
| 15311322 | ENANTIOPURE HAPTENS FOR NICOTINE VACCINE DEVELOPMENT | November 2016 | December 2017 | Abandon | 13 | 1 | 0 | No | No |
| 15299164 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | October 2016 | November 2017 | Abandon | 13 | 1 | 0 | No | No |
| 15299203 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | October 2016 | January 2018 | Abandon | 15 | 1 | 0 | No | No |
| 15299243 | POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE | October 2016 | January 2018 | Abandon | 15 | 1 | 0 | No | No |
| 15091776 | Pyridinoylpiperidines As 5-HT1F Agonists | April 2016 | September 2017 | Abandon | 17 | 0 | 1 | No | No |
| 15073352 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBITORS | March 2016 | June 2018 | Abandon | 27 | 1 | 1 | No | No |
| 14968510 | DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS | December 2015 | August 2017 | Abandon | 20 | 1 | 1 | No | No |
| 14925259 | HETEROCYCLIC COMPOUND AND USE THEREOF | October 2015 | September 2017 | Abandon | 22 | 2 | 0 | No | No |
| 14817827 | Pseudopolymorphic Forms Of A HIV Protease Inhibitor | August 2015 | September 2017 | Abandon | 25 | 1 | 1 | No | No |
| 14744493 | 2',6'-DIOXO-3'-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE COMPOUNDS | June 2015 | October 2017 | Abandon | 28 | 2 | 1 | No | No |
| 14728079 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | June 2015 | September 2017 | Abandon | 27 | 1 | 1 | No | No |
| 14647683 | NOVEL SULFONIC ACID DERIVATIVE COMPOUND, PHOTOACID GENERATOR, CATIONIC POLYMERIZATION INITIATOR, RESIST COMPOSITION, AND CATIONICALLY POLYMERIZABLE COMPOSITION | May 2015 | June 2023 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 14647610 | SYNTHESIS OF UV ABSORBING COMPOUNDS | May 2015 | September 2017 | Abandon | 27 | 2 | 1 | No | No |
| 14439478 | Bruton's Tyrosine Kinase Inhibitors | April 2015 | July 2017 | Abandon | 26 | 2 | 1 | No | No |
| 14618683 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | February 2015 | June 2016 | Abandon | 16 | 1 | 0 | No | No |
| 14417699 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | January 2015 | June 2016 | Abandon | 16 | 1 | 0 | No | No |
| 14413360 | PROCESS FOR IMPROVED OPIOID SYNTHESIS | January 2015 | February 2018 | Abandon | 37 | 3 | 1 | No | No |
| 14564507 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | December 2014 | June 2016 | Abandon | 18 | 1 | 0 | No | No |
| 14382256 | ENHANCER FOR EATING ACTIVITY AND/OR GASTROINTESTINAL ACTIVITY | August 2014 | September 2017 | Abandon | 36 | 3 | 1 | No | No |
| 14239822 | PROCESS FOR PRODUCING BOTH BIOBASED SUCCINIC ACID AND 2,5-FURANDICARBOXYLIC ACID | July 2014 | June 2016 | Abandon | 27 | 2 | 0 | No | No |
| 14369001 | PHENYLTRIAZOLE DERIVATIVE | June 2014 | December 2017 | Abandon | 41 | 3 | 1 | No | No |
| 14266317 | OLIGOMER-CALCIUM CHANNEL BLOCKER CONJUGATES | April 2014 | May 2015 | Allow | 12 | 1 | 0 | Yes | No |
| 14208056 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof. | March 2014 | June 2015 | Allow | 15 | 1 | 0 | No | No |
| 14002031 | ANTI-AMYLOID COMPOUNDS AND METHODS | March 2014 | June 2016 | Abandon | 33 | 1 | 0 | No | No |
| 14110373 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | December 2013 | September 2015 | Allow | 23 | 2 | 0 | Yes | No |
| 13469177 | BENZOCYCLOHEPTENE ACETIC ACIDS | May 2012 | November 2017 | Abandon | 60 | 2 | 1 | No | Yes |
| 12742758 | CEPHALOMANNINE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | November 2010 | December 2014 | Abandon | 55 | 2 | 0 | No | Yes |
| 11941914 | CONJUGATED NITRO ALKENE ANTICANCER AGENTS BASED ON ISOPRENOID METABOLISM | November 2007 | March 2011 | Allow | 40 | 2 | 1 | No | No |
| 11062271 | IMIDAZOLE BASED KINASE INHIBITORS | February 2005 | September 2008 | Allow | 42 | 2 | 1 | No | No |
| 11053752 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | February 2005 | December 2008 | Allow | 46 | 2 | 1 | No | No |
| 11038862 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | January 2005 | September 2008 | Allow | 43 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSAR, ANDREW D.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOSAR, ANDREW D works in Art Unit 1625 and has examined 36 patent applications in our dataset. With an allowance rate of 19.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner KOSAR, ANDREW D's allowance rate of 19.4% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KOSAR, ANDREW D receive 1.58 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KOSAR, ANDREW D is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +34.4% benefit to allowance rate for applications examined by KOSAR, ANDREW D. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.6% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.